Results 231 to 240 of about 38,540 (306)

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

Exploring T-cell bispecific antibodies in gynecologic malignancy. [PDF]

Gynecol Oncol Rep
O'Brien E, Mayer CM, Arend RC.
europepmc   +1 more source

Discrepant Intracranial and Extracranial Responses to Tarlatamab in Relapsed Small‐Cell Lung Cancer With Untreated Brain Metastases: A Case Report

Respirology Case Reports, Volume 14, Issue 5, May 2026.
A 72‐year‐old man with extensive‐stage SCLC developed untreated brain metastases and was treated with tarlatamab before whole‐brain irradiation. After one cycle, marked shrinkage of extracranial lesions and decreases in tumour markers were observed. By contrast, brain MRI showed progression of intracranial metastases.
Eri Hayashi, Hirohisa Kano, Kayo Nakamura, Takamasa Kondo, Akira Nishioka, Manaya Tanaka, Kotaro Aoe, Shuko Mashimo, Daizo Kishino   +8 more
wiley   +1 more source

Bispecific antibodies: unleashing a new era in oncology treatment. [PDF]

Mol Cancer
Shui L, Wu D, Yang K, Sun C, Li Q, Yin R.   +5 more
europepmc   +1 more source

Aptamer‐Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap

Small Science, Volume 6, Issue 5, May 2026.
Aptamer‐functionalized nanocarriers represent a versatile platform for targeted therapy in bone and joint diseases. This review presents five complementary design strategies: free aptamers for soluble targets, bispecific multivalent constructs for enhanced avidity, nanoparticle‐conjugated aptamers for selective tissue accumulation, aptamer‐based ...
Hamdi Al‐Azzani, Djandan Tadum Arthur Vithran, Syeda Sundas Batool, Malek Mohammed Ali Alshabi, Wenhu Zhou, Xiaoqiang Mao   +5 more
wiley   +1 more source

Current immunotherapeutic approaches for relapsed/refractory follicular lymphoma: bispecific antibodies and CAR T-Cell therapies. [PDF]

Blood Res
Park SY, Min GJ.
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Emerging Risk of <i>Campylobacter</i> spp. Infection Associated With Anti-BCMA and Anti-GPRC5D Bispecific Antibodies. [PDF]

Open Forum Infect Dis
Bilbao I, Ansón M, Villar S, Pineda I, Gárriz L, Pina-Sánchez M, Tamariz-Amador LE, Rodríguez-Otero P, Yuste JR, Del Pozo JL.   +9 more
europepmc   +1 more source

Transcriptional Reinforcement of the HER2–RAS Network in HER2‐Positive Gastric Cancer: The RUNX–SOS1 Axis in Context

Cancer Science, Volume 117, Issue 5, Page 1235-1243, May 2026.
RUNX‐dependent transcriptional control of SOS1 reinforces HER2–RAS signaling and may attenuate responses to HER2‐targeted therapies in HER2‐positive gastric cancer. ABSTRACT HER2‐positive gastric cancer represents a distinct molecular subtype characterized by chromosomal instability, variable HER2 amplification, and substantial intratumoral ...
Tatsuya Masuda, Takayoshi Watanabe, Toshinori Ozaki, Yasuhiko Kamikubo   +3 more
wiley   +1 more source

Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis. [PDF]

Blood Adv
van Besien H, Easwar N, Demetres M, Pasciolla M, Shore T, Leonard J, Barker J, Martin P, Yamshon S.   +8 more
europepmc   +1 more source